Test-Retest Reliability of the WB6Dim Digital Well-Being Tool: A 3-Day Interval Study (WB6Dim-TRT)

Psychometric Validation of Test-Retest Reliability of the WB6Dim Digital Self-Assessment Tool for Well-Being Using a 3-Day Interval Protocol and Contamination Control

This study aims to establish the test-retest reliability of the WB6Dim digital self-assessment tool across its eight well-being dimensions, using a 3-day interval protocol designed to minimize the probability of genuine well-being changes between assessments.

Participants complete the 28-item WB6Dim questionnaire at baseline (T1) and again 3 days later (T2). A single contamination control question at T2 identifies participants who experienced a significant life event during the interval; these pairs are excluded from primary ICC analyses and retained for exploratory analyses.

An optional third assessment at 9 weeks (T3) provides preliminary exploratory data on sensitivity to change following access to a well-being program. T3 is not part of the primary design.

Study Overview

• Status: Recruiting
• Conditions: Psychological Well Being

Detailed Description

The first validation study of the WB6Dim instrument (NCT07301879) established strong internal consistency and convergent validity across N=295 participants. Test-retest reliability was assessed over a 14-day interval on N=92 usable pairs, yielding preliminary ICC estimates ranging from .49 to .77. However, the 14-day interval is methodologically suboptimal for a dynamic monitoring tool: real-life events occurring during two weeks cannot be distinguished from instrument instability, and confidence intervals were wide due to the limited number of pairs.

The present study addresses these limitations through three improvements. First, the interval is reduced to 3 days, substantially reducing contamination risk while avoiding memory-based response bias. Second, a contamination control question is administered at T2 to identify and exclude pairs where a significant life event occurred. Third, the target of N=220 usable pairs produces 95% confidence intervals with maximum width of .20 across all dimensions, meeting the precision threshold for definitive psychometric publication.

Only the 28 WB6Dim items are administered, with no additional gold-standard scales, reducing response burden to approximately 3 minutes per session. Participant matching is performed via email address.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: quentin ALITTA; Phone Number: +33686505361; Email: quentin.alitta@gmail.com

Study Locations

• France
  • Bandol, France, 83150
    • Recruiting
    • Clover Link
    • Contact: ALITTA quentin; Phone Number: +33686505361; Email: quentin.alitta@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adult volunteers recruited from a French health and well-being newsletter subscriber base. Not selected based on medical conditions. Represents the general adult population with an interest in personal well-being and health prevention.

Description

Inclusion Criteria:

• Adults aged 18 years or older
• Able to read and understand French
• Access to an internet-connected device
• Willing to complete the WB6Dim questionnaire at T1 and T2
• Consent to anonymous data collection for research purposes

Exclusion Criteria:

• Under 18 years of age
• Unable to read or understand French

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Cohort C - Test-Retest Reliability; Adult volunteers recruited from a health and well-being newsletter subscriber base. Participants complete the 28-item WB6Dim digital self-assessment at baseline (T1) and again 3 days later (T2). A contamination control question at T2 identifies participants who experienced a significant life event during the interval. An optional third assessment (T3) is completed at 9 weeks by participants who voluntarily accessed a well-being program after T2 completion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Test-Retest Reliability (ICC) of the WB6Dim Internal Tension Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Sleep and Recovery Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Energy Reservoir Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Self-Esteem Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Emotional Climate Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Cognitive Saturation Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Hyperconnection Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1.Higher values indicate greater temporal stability.	Day 0 to Day 3
Test-Retest Reliability (ICC) of the WB6Dim Perceived Autonomy Dimension	ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.	Day 0 to Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Contamination Rate at T2	Proportion of T1/T2 pairs excluded due to a significant life event reported at T2 contamination control question. Reported as percentage.	Day 3
ICC Comparison Between Contamination-Free and Contaminated Pairs	Exploratory comparison of ICC(1,1) estimates across all 8 WB6Dim dimensions between contamination-free and contaminated pairs, to assess direction and magnitude of contamination effects.	Day 0 to Day 3

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory Sensitivity to Change - Sleep and Recovery	Pre-post change score (T1 to T3) and Cohen's d for the Sleep and Recovery dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Internal Tension	Pre-post change score (T1 to T3) and Cohen's d for the Internal Tension dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Energy Reservoir	Pre-post change score (T1 to T3) and Cohen's d for the Energy Reservoir dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Self-Esteem	Pre-post change score (T1 to T3) and Cohen's d for the Self-Esteem dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Emotional Climate	Pre-post change score (T1 to T3) and Cohen's d for the Emotional Climate dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Cognitive Saturation	Pre-post change score (T1 to T3) and Cohen's d for the Cognitive Saturation dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Hyperconnection	Pre-post change score (T1 to T3) and Cohen's d for the Hyperconnection dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9
Exploratory Sensitivity to Change - Perceived Autonomy	Pre-post change score (T1 to T3) and Cohen's d for the Perceived Autonomy dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.	Day 0 to Week 9

Collaborators and Investigators

• Sponsor: Clover Link
• Investigators: Study Chair: Frédérique MD, PhD RETORNAZ, MD, PhD, European Hospital, Unit of Care and Research in Internal Medicine and Infectious Diseases.

Publications and helpful links

General Publications

• Alitta Q. Validation Study of the WB6Dim Digital Self-Assessment Tool for Well-Being Using Gold-Standard Psychometric Scales. ClinicalTrials.gov NCT07301879. First posted 2025-12-24.

Helpful Links

• First validation study of the WB6Dim instrument (Cohorts A and B)

Study record dates

Study Major Dates

• Study Start (Actual): February 19, 2026
• Primary Completion (Estimated): February 22, 2026
• Study Completion (Estimated): May 9, 2026

Study Registration Dates

• First Submitted: February 19, 2026
• First Submitted That Met QC Criteria: February 19, 2026
• First Posted (Actual): February 25, 2026

Study Record Updates

• Last Update Posted (Actual): February 25, 2026
• Last Update Submitted That Met QC Criteria: February 19, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: well-being; Psychometric validation; Test-retest reliability; Workplace well-being; Intraclass correlation; Digital self-assessment; WB6Dim
• Additional Relevant MeSH Terms: Behavior; Personal Satisfaction; Psychological Well-Being
• Other Study ID Numbers: WB6Dim-C-2026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: 13:12All collected data are fully anonymized at the point of entry. No individual-level identifiable data are stored or processed. Participant email addresses are used solely for matching T1 and T2 responses and are not retained after study completion. All analyses are conducted on aggregated, pseudonymized numerical data only. IPD sharing is therefore not applicable.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No